Report cover image

Europe High Potency API’s Market Size- By Type, By Synthesis, By Therapeutic Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Publisher SPER Market Research Pvt. Ltd.
Published Jul 15, 2024
Length 154 Pages
SKU # SPER19060798

Description

Europe High Potency API’s Market Size- By Type, By Synthesis, By Therapeutic Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033


Europe High Potency API’s Market Introduction and Overview

According to SPER market research, ‘Europe High Potency API’s Market Size- By Type, By Synthesis, By Therapeutic Application – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ state that the Europe High Potency API’s Market is predicted to reach USD 13.48 billion by 2033 with a CAGR of 8.95%.

The pharmacological compounds with high potency are those that show effects at very low doses. Their keen interest in the state-of-the-art medications under development underscores their significance and potential uses. The use of high potency active pharmaceutical ingredients (HPAPI) in the treatment of serious illnesses is growing in the healthcare industry because they are more effective at much lower dosage levels than standard APIs.

High Potency Active Pharmaceutical Ingredients (HPAPIs) were a major industry in Europe prior to the COVID-19 pandemic. Due to reduced manufacturing capacity, lockdown procedures, and disruptions in international supply chains, the production and delivery of HPAPIs faced difficulties throughout the region during the epidemic.

Scope of the Report:

Report Metric Details
Market size available for
years 2020-2033
Base year considered 2023
Forecast period 2024-2033

Segments covered By Type, By Synthesis, By Therapeutic Application

Regions covered France, Germany, Italy, Spain, United Kingdom, Rest of Europe

Companies Covered AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan Inc., Novartis International AG, Pfizer, Inc., and Sanofi.

Europe High Potency API’s Market Segmentation:

By Type: Based on the Type, Europe High Potency API’s Market is segmented as; Innovative high potency API’s, Generic high potency API’s.

By Synthesis: Based on the Synthesis, Europe High Potency API’s Market is segmented as; Biotech high potency API’s, Synthetic high potency API’s.

By Therapeutic Application: Based on the Therapeutic Application, Europe High Potency API’s Market is segmented as; Oncology, Glaucoma, Hormonal Balance.

By Region: This research also includes data for France, Germany, Italy, Spain, United Kingdom, Rest of Europe.

Table of Contents

154 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe High Potency API’s Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe High Potency API’s Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe High Potency API’s Market
7. Europe High Potency API’s Market, By Type (USD Million) 2020-2033
7.1. Europe High Potency API’s Market Size, Share and Forecast, By Type, 2020-2026
7.2. Europe High Potency API’s Market Size, Share and Forecast, By Type, 2027-2033
7.3. Innovative high potency API’s
7.4. Generic high potency API’s
8. Europe High Potency API’s Market, By Synthesis (USD Million) 2020-2033
8.1. Europe High Potency API’s Market Size, Share and Forecast, By Synthesis, 2020-2026
8.2. Europe High Potency API’s Market Size, Share and Forecast, By Synthesis, 2027-2033
8.3. Biotech high potency API’s
8.4. Synthetic high potency API’s
9. Europe High Potency API’s Market, By Therapeutic Application (USD Million) 2020-2033
9.1. Europe High Potency API’s Market Size, Share and Forecast, By Therapeutic Application, 2020-2026
9.2. Europe High Potency API’s Market Size, Share and Forecast, By Therapeutic Application, 2027-2033
9.3. Oncology
9.4. Glaucoma
9.5. Hormonal Balance
10. Europe High Potency API’s Market Forecast, 2020-2033 (USD Million)
10.1. Europe High Potency API’s Market Size and Market Share
11. Europe High Potency API’s Market, By Region, 2020-2033 (USD Million)
11.1. Europe High Potency API’s Market Size and Market Share By Region (2020-2026)
11.2. Europe High Potency API’s Market Size and Market Share By Region (2027-2033)
11.3. France
11.4. Germany
11.5. Italy
11.6. Spain
11.7. United Kingdom
11.8. Rest of Europe
12. Company Profile
12.1. AbbVie Inc.
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Boehringer Ingelheim
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Bristol-Myers Squibb
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Eli Lilly and Company
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Merck & Co., Inc
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Mylan Inc.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Novartis International AG
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Pfizer, Inc.
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Sanofi
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. Reference Links
15. List of Abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us